Ravi Bhatia1, H Joachim Deeg. 1. Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA. rbhatia@coh.org
Abstract
PURPOSE OF REVIEW: Treatment-related myelodysplastic syndrome (t-MDS) is a serious complication of cancer treatment. Here we review recent advances in knowledge of the risk factors, pathogenesis, and treatment of t-MDS. RECENT FINDINGS: Recent studies have provided important new information regarding genetic risk factors that may predispose individual patients to develop t-MDS after exposure to cytotoxic therapeutic agents and that may be used to predict individuals at enhanced risk for this complication. The role of specific candidate genes associated with commonly involved genetic lesions in the pathogenesis of t-MDS has also been investigated. Finally, factors determining outcomes of transplantation treatment for this disorder have been elucidated. Hematopoietic cell transplantation provides potentially curative therapy for t-MDS, but additional improvements are necessary to improve outcomes. SUMMARY: Improved understanding of genetic risk factors is expected to facilitate early identification of patients at risk for t-MDS, guiding therapeutic decision making, and allowing early application of preventive or therapeutic strategies.
PURPOSE OF REVIEW: Treatment-related myelodysplastic syndrome (t-MDS) is a serious complication of cancer treatment. Here we review recent advances in knowledge of the risk factors, pathogenesis, and treatment of t-MDS. RECENT FINDINGS: Recent studies have provided important new information regarding genetic risk factors that may predispose individual patients to develop t-MDS after exposure to cytotoxic therapeutic agents and that may be used to predict individuals at enhanced risk for this complication. The role of specific candidate genes associated with commonly involved genetic lesions in the pathogenesis of t-MDS has also been investigated. Finally, factors determining outcomes of transplantation treatment for this disorder have been elucidated. Hematopoietic cell transplantation provides potentially curative therapy for t-MDS, but additional improvements are necessary to improve outcomes. SUMMARY: Improved understanding of genetic risk factors is expected to facilitate early identification of patients at risk for t-MDS, guiding therapeutic decision making, and allowing early application of preventive or therapeutic strategies.
Authors: Nicolaus Kröger; Tatjana Zabelina; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Rodrigo Martino; Zi Yi Lim; Francesco Onida; Christoph Schmid; Laurent Garderet; Marie Robin; Michael van Gelder; Reinhard Marks; Argiris Symeonidis; Guido Kobbe; Theo de Witte Journal: Haematologica Date: 2010-10-22 Impact factor: 9.941
Authors: Derek L Stirewalt; Andrew J Mhyre; Mario Marcondes; Era Pogosova-Agadjanyan; Nissa Abbasi; Jerald P Radich; H Joachim Deeg Journal: Br J Haematol Date: 2007-12-19 Impact factor: 6.998
Authors: Chunkang Chang; Barry E Storer; Bart L Scott; Eileen M Bryant; Howard M Shulman; Mary E Flowers; Brenda M Sandmaier; Robert P Witherspoon; Richard A Nash; Jean E Sanders; Antonio Bedalov; John A Hansen; Bruce E Clurman; Rainer Storb; Frederick R Appelbaum; H Joachim Deeg Journal: Blood Date: 2007-05-08 Impact factor: 22.113
Authors: Nathan A Ellis; Dezheng Huo; Ozlem Yildiz; Lisa J Worrillow; Mekhala Banerjee; Michelle M Le Beau; Richard A Larson; James M Allan; Kenan Onel Journal: Blood Date: 2008-04-21 Impact factor: 22.113
Authors: Ryan K Funk; Taylor J Maxwell; Masayo Izumi; Deepa Edwin; Friederike Kreisel; Timothy J Ley; James M Cheverud; Timothy A Graubert Journal: Blood Date: 2008-06-13 Impact factor: 22.113
Authors: Timothy A Graubert; Michelle A Payton; Jin Shao; Richard A Walgren; Ryan S Monahan; John L Frater; Mark A Walshauser; Mike G Martin; Yumi Kasai; Matthew J Walter Journal: PLoS One Date: 2009-02-25 Impact factor: 3.240
Authors: Ting Zhou; Paul Hasty; Christi A Walter; Alexander J R Bishop; Linda M Scott; Vivienne I Rebel Journal: Exp Hematol Date: 2013-04-30 Impact factor: 3.084
Authors: A Boquoi; S M Banahan; A Mohring; I Savickaite; J Strapatsas; B Hildebrandt; G Kobbe; N Gattermann; R Haas; T Schroeder; U Germing; R Fenk Journal: Ann Hematol Date: 2022-03-09 Impact factor: 3.673
Authors: Laura Guerenne; Stéphanie Beurlet; Mohamed Said; Petra Gorombei; Carole Le Pogam; Fabien Guidez; Pierre de la Grange; Nader Omidvar; Valérie Vanneaux; Ken Mills; Ghulam J Mufti; Laure Sarda-Mantel; Maria Elena Noguera; Marika Pla; Pierre Fenaux; Rose Ann Padua; Christine Chomienne; Patricia Krief Journal: J Hematol Oncol Date: 2016-01-27 Impact factor: 17.388